Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02879617 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 2
- Study locations
NCT02879617: Completed Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
NCT02879617 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Academic Thoracic Oncology Medical Investigators Consortium. The registered enrollment target is 47 participants, below the 284-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02879617, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
Primary Outcome
Median length of time from the start of treatment from start of treatment to death from any cause.
Conditions Studied
Interventions
- DRUG durvalumab
Study Locations (2)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- Simmons Comprehensive Cancer Center - UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2022-06-04 |
| Phase | Phase 2 |
What the finished NCT02879617 record still lists
NCT02879617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 284-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which durvalumab is the first listed.
NCT02879617 reports a single indexed study location in Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT02879617 about?
NCT02879617 is a clinical study titled "A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients". This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
What is the current status of trial NCT02879617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2017-04-04. Estimated completion is 2022-06-04.
What conditions does trial NCT02879617 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT02879617?
The interventions under investigation include: durvalumab (DRUG).
Who is sponsoring clinical trial NCT02879617?
This trial is sponsored by Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02879617 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02879617's enrollment target sits among peer trials
47 44th of 59 higher than 16 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
RECRUITING · Phase 2
-
Pembrolizumab for Advanced NSCLC and PS 2-3
RECRUITING · Phase 2
-
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ACTIVE NOT RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI